Would you like to participate ask a question join the surfers in our next episode?

S2-E16 — Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment

Mazen Noureddin joins the Surfers to discuss his work determining the cost-effectiveness of non-invasive NASH testing and treatment in Type 2 diabetics and the broader population. The discussion shifts to considering broader treatment issues.

Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment — Dr. Noureddin started the discussion by providing a history of cost-effectiveness research in NASH and NAFLD. At a population level, biopsy turns out never to be cost-effective while less expensive tests almost always are. As the group brainstormed implications and new questions, they touched on theories on how cost-effectiveness for F3 and F2 patients might differ, and even how chronic therapies and sequential use of specific medicines might reflect cost-effective issues. An enlightening way to think about testing and treatment today, and how these will evolve over time.

Request Transcript of This Episode
Request Transcript
First
Last